医学
重症监护医学
持续气道正压
精密医学
个性化医疗
第一行
生物信息学
病理
阻塞性睡眠呼吸暂停
内科学
生物
作者
Jayne C. Carberry,Jason Amatoury,Danny J. Eckert
出处
期刊:Chest
[Elsevier]
日期:2017-06-17
卷期号:153 (3): 744-755
被引量:201
标识
DOI:10.1016/j.chest.2017.06.011
摘要
OSA is a heterogeneous disorder. If left untreated, it has major health, safety, and economic consequences. In addition to varying levels of impairment in pharyngeal anatomy (narrow/collapsible airway), nonanatomical "phenotypic traits" are also important contributors to OSA for most patients. However, the majority of existing therapies (eg, CPAP, oral appliances, weight loss, positional therapy, upper airway surgery) target only the anatomical cause. These are typically administered as monotherapy according to a trial and error management approach in which the majority of patients are first prescribed CPAP. Despite its high efficacy, CPAP adherence remains unacceptably low, and second-line therapies have variable and unpredictable efficacies. Recent advances in knowledge regarding the multiple causes of OSA using respiratory phenotyping techniques have identified new targets or "treatable traits" to direct therapy. Identification of the traits and development of therapies that selectively target one or more of the treatable traits has the potential to personalize the management of this chronic health condition to optimize patient outcomes according to precision medicine principles. This brief review highlights the latest developments and emerging therapies for personalized management approaches for OSA.
科研通智能强力驱动
Strongly Powered by AbleSci AI